Liqiao Hou

Study of tumor control probability by stereotactic body radiotherapy with first-generation EGFR-TKIs

Our previous study suggested that patients with advanced epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma treated with first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) followed by standard-dose stereotactic body radiotherapy (SBRT) had a larger area...